Literature DB >> 29715055

Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase.

Sarah A Holstein1, Jens Hillengass1, Philip L McCarthy1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29715055     DOI： 10.1200/JCO.2018.77.9637

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Authors:  Ka Yang; Yu Zhao; Xueqing Nie; Hao Wu; Bo Wang; Chelsi M Almodovar-Rivera; Haibo Xie; Weiping Tang
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

2.  N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge.

Authors:  Shih Chang Hsueh; Weiming Luo; David Tweedie; Dong Seok Kim; Yu Kyung Kim; Inho Hwang; Jung-Eun Gil; Baek-Soo Han; Yung-Hsiao Chiang; Warren Selman; Barry J Hoffer; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-30

3.  Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.

Authors:  Chutirat Jirabanditsakul; Sumana Dakeng; Chutima Kunacheewa; Yaowalak U-Pratya; Weerapat Owattanapanich
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.